Graves Ophthalmopathy - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Graves Ophthalmopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Graves’ Ophthalmopathy: Overview
Graves’ ophthalmopathy, also called Graves’ orbitopathy or Thyroid-associated orbitopathy (TAO), is part of an autoimmune process that can affect the orbital and periorbital tissue, the thyroid gland, and, rarely, the pretibial skin or digits. Generally, occur in patients with hyperthyroidism or a history of hyperthyroidism. Risk factors for thyroid-associated orbitopathy include increased age of onset, duration of Graves’ hyperthyroidism, and smoking. The ocular manifestations of thyroid-associated orbitopathy include eyelid retraction, proptosis, chemosis, periorbital edema, and altered ocular motility with significant functional, social, and cosmetic consequences. The first step in treatment is to reverse the hyperthyroidism with either medication or surgery to remove the thyroid.
“Graves’ ophthalmopathy- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graves’ ophthalmopathy pipeline landscape is provided which includes the disease overview and Graves’ ophthalmopathy treatment guidelines. The assessment part of the report embraces, in depth Graves’ ophthalmopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graves’ ophthalmopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Graves Ophthalmopathy R&D. The therapies under development are focused on novel approaches to treat/improve Graves Ophthalmopathy.
Graves Ophthalmopathy Emerging Drugs Chapters
This segment of the Graves Ophthalmopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Graves Ophthalmopathy Emerging Drugs
Batoclimab (RVT-1401): Immunovant
FcRn is the primary protein responsible for preventing the degradation of IgG antibodies and albumin, the most abundant protein found in the blood. The role of FcRn is to bind to the IgG antibodies in the endosome, and transport them to the cell surface, where they are released back into circulation. RVT-1401 is designed to selectively bind to and inhibit FcRn, thus blocking the recycling of IgG antibodies. Currently, in phase 2 of clinical trials for the treatment of Graves Ophthalmopathy.
Further product details are provided in the report……..
Graves Ophthalmopathy: Therapeutic Assessment
This segment of the report provides insights about the different Graves Ophthalmopathy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Graves Ophthalmopathy
There are approx. 3+ key companies which are developing the therapies for Graves Ophthalmopathy. The companies which have their Graves Ophthalmopathy drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Immunovant and others.
Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Graves Ophthalmopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Graves Ophthalmopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Graves Ophthalmopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Graves Ophthalmopathy drugs.
Graves Ophthalmopathy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Graves Ophthalmopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Graves’ Ophthalmopathy: Overview
Graves’ ophthalmopathy, also called Graves’ orbitopathy or Thyroid-associated orbitopathy (TAO), is part of an autoimmune process that can affect the orbital and periorbital tissue, the thyroid gland, and, rarely, the pretibial skin or digits. Generally, occur in patients with hyperthyroidism or a history of hyperthyroidism. Risk factors for thyroid-associated orbitopathy include increased age of onset, duration of Graves’ hyperthyroidism, and smoking. The ocular manifestations of thyroid-associated orbitopathy include eyelid retraction, proptosis, chemosis, periorbital edema, and altered ocular motility with significant functional, social, and cosmetic consequences. The first step in treatment is to reverse the hyperthyroidism with either medication or surgery to remove the thyroid.
“Graves’ ophthalmopathy- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graves’ ophthalmopathy pipeline landscape is provided which includes the disease overview and Graves’ ophthalmopathy treatment guidelines. The assessment part of the report embraces, in depth Graves’ ophthalmopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graves’ ophthalmopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Graves Ophthalmopathy R&D. The therapies under development are focused on novel approaches to treat/improve Graves Ophthalmopathy.
Graves Ophthalmopathy Emerging Drugs Chapters
This segment of the Graves Ophthalmopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Graves Ophthalmopathy Emerging Drugs
Batoclimab (RVT-1401): Immunovant
FcRn is the primary protein responsible for preventing the degradation of IgG antibodies and albumin, the most abundant protein found in the blood. The role of FcRn is to bind to the IgG antibodies in the endosome, and transport them to the cell surface, where they are released back into circulation. RVT-1401 is designed to selectively bind to and inhibit FcRn, thus blocking the recycling of IgG antibodies. Currently, in phase 2 of clinical trials for the treatment of Graves Ophthalmopathy.
Further product details are provided in the report……..
Graves Ophthalmopathy: Therapeutic Assessment
This segment of the report provides insights about the different Graves Ophthalmopathy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Graves Ophthalmopathy
There are approx. 3+ key companies which are developing the therapies for Graves Ophthalmopathy. The companies which have their Graves Ophthalmopathy drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Immunovant and others.
Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Graves Ophthalmopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Parenteral
- Intramuscular
- Molecule Type
- Small molecules
- Peptides
- Polymer
- Gene Therapy
- Monoclonal antibodies
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Graves Ophthalmopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Graves Ophthalmopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Graves Ophthalmopathy drugs.
Graves Ophthalmopathy Report Insights
- Graves Ophthalmopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Graves Ophthalmopathy drugs?
- How many Graves Ophthalmopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Graves Ophthalmopathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Graves Ophthalmopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Graves Ophthalmopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Immunovant
- RVT-1401
Introduction
Executive Summary
Graves Ophthalmopathy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Graves Ophthalmopathy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Graves Ophthalmopathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Graves Ophthalmopathy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
RVT-1410: Immunovant
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Graves Ophthalmopathy Key Companies
Graves Ophthalmopathy Key Products
Graves Ophthalmopathy- Unmet Needs
Graves Ophthalmopathy- Market Drivers and Barriers
Graves Ophthalmopathy- Future Perspectives and Conclusion
Graves Ophthalmopathy Analyst Views
Graves Ophthalmopathy Key Companies
Appendix
Executive Summary
Graves Ophthalmopathy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Graves Ophthalmopathy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Graves Ophthalmopathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Graves Ophthalmopathy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
RVT-1410: Immunovant
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Graves Ophthalmopathy Key Companies
Graves Ophthalmopathy Key Products
Graves Ophthalmopathy- Unmet Needs
Graves Ophthalmopathy- Market Drivers and Barriers
Graves Ophthalmopathy- Future Perspectives and Conclusion
Graves Ophthalmopathy Analyst Views
Graves Ophthalmopathy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Graves Ophthalmopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Graves Ophthalmopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Graves Ophthalmopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Graves Ophthalmopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
